The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries)
Aim. To evaluate an incidence of oral anticoagulants (OAC) administration during longterm follow-up period in patients with atrial fibrillation (AF) enrolled in outpatient and hospital RECVASA registries.Material and methods. 3169 patients with AF were enrolled in outpatient registries RECVASA (Ryaz...
Saved in:
| Main Authors: | M. M. Loukianov, S. Yu. Martsevich, O. M. Drapkina, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, E. M. Pozdnyakova, T. A. Gomova, E. E. Fedotova, M. N Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, E. Y. Andreenko, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, M. A. Panagopulu, S. A. Boytsov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2019-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES
by: M. M. Loukianov, et al.
Published: (2018-03-01) -
Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries)
by: M. M. Loukianov, et al.
Published: (2020-12-01) -
PATIENTS WITH ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOSPITALIZATION STRUCTURE AND ANTITHROMBOTIC THERAPY (RECVASA AF-KURSK REGISTRY)
by: V. P. Mikhin, et al.
Published: (2017-05-01) -
Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice
by: Yu. P. Skirdenko, et al.
Published: (2022-03-01) -
Anticoagulant-related bleeding in patients with heart failure in combination with chronic obstructive pulmonary disease and atrial fibrillation. Experience with Idarucizumab
by: L. A. Shpagina, et al.
Published: (2020-06-01)